MEPE Antibody (B-6): sc-390608

MEPE Antibody (B-6) is a mouse monoclonal IgG2b antibody that detects matrix extracellular phosphoglycoprotein (MEPE) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MEPE is a 525 amino acid extracellular matrix protein predominantly expressed in osteocytes and the brain, playing a crucial role in regulating bone metabolism by mediating mineralization and demineralization within the osteocyte microenvironment. MEPE features an RGD cell-attachment motif, which is essential for interaction with integrins, facilitating cell adhesion and signaling processes. This interaction is vital for maintaining bone integrity and function, as MEPE influences osteocyte communication and the overall bone remodeling process. MEPE′s ability to regulate bone mineralization links MEPE to significant developmental events such as skeletogenesis, bone regeneration, and odontogenesis. Furthermore, MEPE is secreted in hypophosphatemic osteomalacia tumors, indicating potential involvement in the pathophysiology of bone-related cancers. Defects in the gene encoding MEPE have been associated with osteomalacia, a condition characterized by inadequate bone mineralization, highlighting the importance of MEPE in skeletal health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MEPE Antibody (B-6) References:

1. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.  |  Rowe, PS., et al. 2000. Genomics. 67: 54-68. PMID: 10945470
2. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo.  |  Hayashibara, T., et al. 2004. J Bone Miner Res. 19: 455-62. PMID: 15040834
3. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone.  |  Nampei, A., et al. 2004. J Bone Miner Metab. 22: 176-84. PMID: 15108058
4. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion.  |  Sprowson, AP., et al. 2008. J Orthop Res. 26: 1256-62. PMID: 18383145
5. Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.  |  Hoffman, WH., et al. 2008. Am J Med Genet A. 146A: 2164-8. PMID: 18627046
6. MEPE evolution in mammals reveals regions and residues of prime functional importance.  |  Bardet, C., et al. 2010. Cell Mol Life Sci. 67: 305-20. PMID: 19924383
7. Differentiation of odontoblasts is negatively regulated by MEPE via its C-terminal fragment.  |  Wang, H., et al. 2010. Biochem Biophys Res Commun. 398: 406-12. PMID: 20599717
8. MicroRNA-376a sensitizes cells following DNA damage by downregulating MEPE expression.  |  Sheng, J., et al. 2013. Cancer Biother Radiopharm. 28: 523-9. PMID: 23570370
9. Variants affecting diverse domains of MEPE are associated with two distinct bone disorders, a craniofacial bone defect and otosclerosis.  |  Schrauwen, I., et al. 2019. Genet Med. 21: 1199-1208. PMID: 30287925
10. MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk.  |  Surakka, I., et al. 2020. Nat Commun. 11: 4093. PMID: 33097703

The preferred MEPE antibody is MEPE Antibody (LFMb-33): sc-73635.